Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030465 | 1.00 | KMT2A (0.45) | KMT2AKDM4EL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL6030322 | 0.86 | ALDH1A1 (0.52) | KMT2AKDM4EL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL6031446 | 0.86 | ALDH1A1 (0.52) | KMT2AKDM4EL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL6029664 | 0.79 | PRSS1 (0.42) | KMT2AKDM4EL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL6031467 | 0.79 | PRSS1 (0.42) | KMT2AKDM4EL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL6030253 | 0.79 | KDM4E (0.42) | KMT2AKDM4EL3MBTL1ALDH1A1NAAA | |
| SCHEMBL6030466 | 0.78 | KDM4E (0.41) | KMT2AKDM4EL3MBTL1ALDH1A1NAAA | |
| SCHEMBL6030153 | 0.70 | MAPT (0.44) | KMT2AKDM4EL3MBTL1ALDH1A1POLB | |
| SCHEMBL6030673 | 0.70 | PKM (0.42) | KMT2AKDM4EL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL10627226 | 0.70 | PTK2 (0.50) | KMT2AKDM4EL3MBTL1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064122-B2 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | PNLIP, LIPC, CEL | KMT2A 3645/4885KDM4E 2643/4885L3MBTL1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.